Parkinson Disease Clinical Trials in Farmington Hills, Michigan

7 studies are recruiting for parkinson disease in Farmington Hills, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

   A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Site-015, Farmington Hills, Michigan

   Locations

   22 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06976268 on ClinicalTrials.gov

2. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

   This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. P…

   Stage

   Phase 2

   Ages

   30 to 80

   Site

   Quest Research Institute - Alcanza - PPDS (Site #201), Farmington Hills, Michigan

   Locations

   30 in total

   Run by

   Appello Pharmaceuticals, Inc.

   See if you can join NCT07432958 on ClinicalTrials.gov

3. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

   The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic p…

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Quest Research Institute, Farmington Hills, Michigan

   Locations

   72 in total

   Run by

   Neuron23 Inc.

   See if you can join NCT06680830 on ClinicalTrials.gov

4. Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

   A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Quest Research Institute, Farmington Hills, Michigan

   Locations

   5 in total

   Run by

   Hillhurst Biopharmaceuticals, Inc.

   See if you can join NCT07005180 on ClinicalTrials.gov

5. A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

   The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

   Stage

   Phase 2

   Ages

   45 to 75

   Site

   Quest Research Institute (Neurology), Farmington Hills, Michigan

   Locations

   46 in total

   Run by

   AskBio Inc

   See if you can join NCT06285643 on ClinicalTrials.gov

6. A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

   The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

   Stage

   Phase 1

   Ages

   30 to 85

   Site

   QUEST Research Institute, Farmington Hills, Michigan

   Locations

   14 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06809400 on ClinicalTrials.gov

7. A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

   The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Quest Research Institute, Farmington Hills, Michigan

   Locations

   27 in total

   Run by

   Impax Laboratories, LLC

   See if you can join NCT06765668 on ClinicalTrials.gov